Gender-specific Differences in Patients with Psoriatic Arthritis Receiving Ustekinumab or Tumour Necrosis Factor Inhibitor: Real-world Data
Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead089
These real-world data from PsABio on gender differences suggest that, at the start of biologic treatment, females have a worse clinical picture of PsA than males. In coming to these conclusions and others, this study sought to investigate effects of gender on disease characteristics and treatment impact in patients with PsA.
Additionally, although treatment improvements were seen in both genders, a lower percentage of women reached a favourable disease state of low or minimal disease activity at 1 year when compared to males. Indeed, more women also stopped/switched biologics due to both lower effectiveness of the treatment and AEs. This calls for a better understanding of the underlying disease mechanisms which underly these differences, an understanding which may improve therapeutic management in females with PsA.